Share movements -- or a lack thereof -- show investors aren't sure the takeover will go through as planned.
The chemical giant is throwing resources at its agriculture business at the expense of its other units -- which might be a boon for rival 3M.
JPMorgan thinks Monsanto is a good buy today. This Fool begs to differ.
Just when the Dow-DuPont merger was looking like a done deal, the U.S. Senate decided to get involved. Is this cause for alarm?
DuPont's management covered a lot of topics on its recent second-quarter earnings call, but there were three things that it clearly thinks are especially important.
These top agricultural and farming stocks could provide great returns in the long run.
The Lautenberg Act has passed both houses of Congress and is headed to the president's desk for signature. Here's why chemical investors don't need to worry.
After treading water for a failed acquisition attempt for much of 2015, Monsanto jumped after being courted by Bayer last month.
The company has a lot going for it, but its valuation is high compared with other manufacturers. Too high to invest?
Through a merger with Dow Chemical, followed by a three-way split, DuPont hopes to improve its fortunes. But the big beneficiary might not be DuPont's shareholders: it might be 3M's.